501 related articles for article (PubMed ID: 25819228)
21. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
22. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
[TBL] [Abstract][Full Text] [Related]
24. Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.
Righi S; Novero D; Godio L; Bertuzzi C; Bacci F; Agostinelli C; Sagramoso C; Rossi M; Piccioli M; Gazzola A; Mannu C; Roncador G; Sabattini E
Hum Pathol; 2022 Jun; 124():67-75. PubMed ID: 35339566
[TBL] [Abstract][Full Text] [Related]
25. Highly sensitive
Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
[TBL] [Abstract][Full Text] [Related]
26. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.
Swerdlow SH; Kuzu I; Dogan A; Dirnhofer S; Chan JK; Sander B; Ott G; Xerri L; Quintanilla-Martinez L; Campo E
Virchows Arch; 2016 Mar; 468(3):259-75. PubMed ID: 26454445
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP; Correa JG; Battram AM; Osuna M; Rivas-Delgado A; Rodríguez-Lobato LG; Cardús O; Tovar N; Cibeira MT; Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C
Br J Haematol; 2023 Jan; 200(2):187-196. PubMed ID: 36210485
[TBL] [Abstract][Full Text] [Related]
28. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
29. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
Awata-Shiraiwa M; Yokohama A; Kanai Y; Gotoh N; Kasamatsu T; Handa H; Saitoh T; Murakami H; Hirato J; Ikota H; Tsukamoto N
Acta Haematol; 2023; 146(5):384-390. PubMed ID: 36917966
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
[No Abstract] [Full Text] [Related]
31. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
32. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
35. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
[TBL] [Abstract][Full Text] [Related]
37. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract][Full Text] [Related]
38. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
39. Aggressive Lymphoplasmacytic Neoplasm With an Unusual In-frame Deletion of
Yan M; Meyerson H; Oduro KA; Shetty S; Yoest J
Int J Surg Pathol; 2024 Feb; 32(1):5-10. PubMed ID: 37093763
[TBL] [Abstract][Full Text] [Related]
40. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
